CD8A and neoplasm: Although growing evidence points towards the cDC1 subtype as the ideal platform for next-generation DC vaccines due to its central role in tumour immunity and its superior ability to prime CD8+ T cells [99], a better understanding of DC biology and the immunosuppressive mechanisms that drive DC dysfunction remains essential if DC vaccine efficacy is to be augmented.